ResMed, 1300 Smiles, Cochlear: The bull case for 2014

3 high-profit margin healthcare companies with earnings growth potential.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When you look over an industry it's smart to start at the top of the company rankings by market capitalisation and performance to get a gauge of a stock's outlook. Not that you shouldn't consider smaller companies because they can be real growers with the right business model. The market leaders are the standard and give you an idea of whether the industry is price competitive or attracts a premium.

Looking at healthcare equipment and services, I screened out companies that have net profit margins over 15% and then chose two market leaders and an up-and-coming business to see which may be a better bull case.

Cochlear (ASX: COH) and ResMed (ASX: RMD) are major industry leaders with respective market caps of $3.4 billion and $7.4 billion. 1300 Smiles (ASX: ONT) weighs in at just $141 million.

Cochlear deals in bionic hearing devices, while ResMed concentrates on respiratory disorder-related devices, so not much competitive overlap there. 1300 Smiles provides dental professionals with dental surgeries, practice management and other administrative services.

Investor earnings

Looking at investor earnings, the highest dividend yield is Cochlear's 4.2% and for net profit margin ResMed leads with 20.3%. High net profit margins are doubly good when a stock has a high earnings growth rate. This is where ResMed squeaked out ahead of 1300 Smiles, with a past five-year earnings per share annual growth rate of a compound 24.7%, versus 18% for 1300 Smiles. Cochlear was way back in third place.

Value levels

The market is expecting good growth from all three and all have PE ratios in the mid 20s, with Cochlear the highest at 25. Due to that and Cochlear's lower five-year EPS growth rate of a compound annual 2.3%, I think ResMed and 1300 Smiles are better value at current prices.

Forecast earnings prospects

2014's analyst forecasts favour 1300 Smiles, projecting the largest earnings percentage gains of the three. 1300 Smiles is a small business that grows by adding more dental practices to its service network. There are also many private practices that can be either acquired or attracted into its circle. Forecast earnings gains are 16% to ResMed's 13%. Cochlear's performance is also expected to improve in 2015.

Foolish takeaway

Based on the topics here the race is mostly between ResMed and 1300 Smiles. I like 1300 Smiles' EPS growth prospects. It also has a longer history of paying dividends and a higher dividend yield (currently at 2.8%) than ResMed.

Of the three, I am most bullish about 1300 Smiles. Although it is not an international company like ResMed and Cochlear, it has a lot of room to grow domestically and there's a large number of privately practicing dentists and orthodontists that could join the network over time. Like a chain store growing across a country, 1300 Smiles can do the same with not a lot of competition.

Motley Fool contributor Darryl Daté-Shappard does not own shares in any company mentioned. 

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »